Covance: name change to Labcorp Drug Development
Contract research organization (CRO) Covance has announced it will rebrand as Labcorp Drug Development at the end of June 2021. The move comes six years after Labcorp and Covance signed a $6.1b USD merger agreement in February 2015.
Paul Kirchgraber, CEO of the company currently branded Covance by Labcorp, said in a statement, “As we transition, your studies will be delivered by the same talented, committed teams, on the same innovative scientific instruments, with a shared commitment to delivering drugs/devices to market sooner … Over time, you will notice more connectivity between our drug development and diagnostic capabilities—in oncology, biomarkers and companion diagnostics, data analytics, commercialization services and more.”
